Literature DB >> 12907627

Transcription factor c-Jun activation represses mdr-1 gene expression.

Ze-Hong Miao1, Jian Ding.   

Abstract

Expression of mdr-1 is complex and highly regulated. Several lines of evidence indirectly suggest that transcription factor c-Jun may negatively regulate human mdr-1 gene expression. We recently found that salvicine, a novel topoisomerase II inhibitor, is cytotoxic for multidrug resistance (MDR) tumor cells and down-regulates mdr-1 expression in MDR K562/A02 cells. Salvicine also stimulates a significant increase in the level of c-jun mRNA in HL60 cells. This study investigated the relationship between c-Jun activation and down-regulation of mdr-1 expression by salvicine in K562/A02 cells. Reverse-transcription PCR and Western blotting analyses revealed that salvicine suppressed mdr-1 expression in MDR cells and promoted c-jun expression in both MDR and parental K562 cells. Moreover, levels of c-jun expression were enhanced by salvicine before reduction of mdr-1 expression in K562/A02 cells. Furthermore, c-jun antisense oligodeoxynucleotides prevented salvicine-stimulated enhancement of c-Jun protein and reduction of mdr-1 gene expression, but did not affect the increase in c-jun mRNA levels. Salvicine promoted phosphorylation of c-Jun-N-terminal kinase and c-Jun protein in MDR K562/A02 and parental K562 cells. Electrophoretic mobility shift assay analysis showed that salvicine enhanced DNA binding activity of transcription factor activator protein 1. Additionally, c-jun antisense oligodeoxynucleotides also inhibited salvicine-induced apoptosis and cytotoxicity in MDR and parental K562 cells. A possible pathway emerges from these results: salvicine stimulates c-Jun-N-terminal kinase phosphorylation and activation, resulting in c-Jun phosphorylation and activation. Activated c-Jun promotes expression of c-jun itself, represses mdr-1 transcription, and triggers pro-apoptotic signals, resulting in low mdr-1 expression and cell death. The present results demonstrate that transcription factor c-Jun plays a principal role in down-regulation of mdr-1 expression and induction of apoptosis in salvicine-treated human MDR K562/A02 cells, providing new insights into the complicated mechanisms regulating mdr-1 expression. The findings also suggest that c-Jun might be a potential drug target for circumventing tumor MDR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907627

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model.

Authors:  Bing Yu; Mei-Hong Li; Wei Wang; Ying-Qing Wang; Yi Jiang; Sheng-Ping Yang; Jian-Min Yue; Jian Ding; Ze-Hong Miao
Journal:  J Mol Med (Berl)       Date:  2012-03-10       Impact factor: 4.599

Review 2.  Biological screening of natural products and drug innovation in China.

Authors:  Ming-Wei Wang; Xiaojiang Hao; Kaixian Chen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

3.  Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction.

Authors:  Yi Jiang; Ze-Hong Miao; Lei Xu; Bing Yu; Jing-Xu Gong; Lin-Jiang Tong; Yi Chen; Zhao-Li Zhou; Hong-Chun Liu; Yi Wang; Yue-Wei Guo; Jian Ding
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

4.  Preventing polyglutamine-induced activation of c-Jun delays neuronal dysfunction in a mouse model of SCA7 retinopathy.

Authors:  Karine Merienne; James Friedman; Masayuki Akimoto; Gretta Abou-Sleymane; Chantal Weber; Anand Swaroop; Yvon Trottier
Journal:  Neurobiol Dis       Date:  2006-12-26       Impact factor: 5.996

5.  BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.

Authors:  Yo-Ting Tsai; Gerard Lozanski; Amy Lehman; Ellen J Sass; Erin Hertlein; Santosh B Salunke; Ching-Shih Chen; Michael R Grever; John C Byrd; David M Lucas
Journal:  Leuk Res       Date:  2015-09-05       Impact factor: 3.156

6.  Synaptonuclear messenger PRR7 inhibits c-Jun ubiquitination and regulates NMDA-mediated excitotoxicity.

Authors:  Dana O Kravchick; Anna Karpova; Matous Hrdinka; Jeffrey Lopez-Rojas; Sanda Iacobas; Abigail U Carbonell; Dumitru A Iacobas; Michael R Kreutz; Bryen A Jordan
Journal:  EMBO J       Date:  2016-07-25       Impact factor: 11.598

7.  Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.

Authors:  Luyuan Zhang; Sinan Sun; Yumin Wang; Yongzhen Mo; Fang Xiong; Shanshan Zhang; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Hao Chen; Can Guo
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 8.  Newly discovered angiogenesis inhibitors and their mechanisms of action.

Authors:  Ze-hong Miao; Jian-ming Feng; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

9.  Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells.

Authors:  Baoan Chen; Jian Cheng; Mingfang Shen; Feng Gao; Wenlin Xu; Huilin Shen; Jiahua Ding; Chong Gao; Qian Sun; Xinchen Sun; Hongyan Cheng; Guohong Li; Wenji Chen; Ningna Chen; Lijie Liu; Xiaomao Li; Xuemei Wang
Journal:  Int J Nanomedicine       Date:  2009-04-01

10.  Troglitazone reverses the multiple drug resistance phenotype in cancer cells.

Authors:  Gerald F Davies; Bernhard H J Juurlink; Troy A A Harkness
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.